99% High Assay Anti-Rheumatism Pharmaceutical Baricitinib CAS 1187594-09-7

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Baricitinib
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Appearance: White Powder
• CAS No: 1187594-09-7
• Shelf Life: 2 Years
• Test Method: HPLC
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Market: Worldwide
• Service: Welcome to Visit Us
• Delivery Time: 7-10days
• Mf: C16h17n7o2s
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

99% High Assay Anti-Rheumatism Pharmaceutical Baricitinib 1187594-09-7

Specification of Analysis

 

Items	Standards	Results
Appearance	White or off-white solid powder	Complies
Identification	By IR	Complies
	By HPLC	Complies
Solubility	Soluble in DMSO, sparingly soluble in THF and Ace tone, slightly soluble in meth anol,  and 0.1N HCl, very sightly soluble in ethanol and dichlo romethane, practically insoluble in water	Complies
Melting Point	213.0ºC~215.0ºC	213.1ºC~214.6ºC
Water Content	≤ 0.50%	0.08%
Heavy Metals	≤ 20ppm	Complies
Residue on Ignition	≤ 0.20%	0.08%
Relative Substance	Any single impurity: ≤0.10%	0.07%
	Total Impurities: ≤1.00%	0.18%
Assay                  (on the anhydrous basis)	98.0%~102.0%	99.90%
Particle Size	D90: ≤60µm	Complies
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a cool place

Description: 

Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for use in the European Union and the United States.

Indications

1. It is used for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. Patients with intolerance to one or more anti-rheumatic drugs can be treated with this product. This product can be treated as a single agent or combined with a Combined treatment of methotrexate in Chemicalbook therapy. The efficacy of baricitinib in the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus and other diseases is currently in phase II clinical stage.
2. Used in the field of scientific research and chemical reagent.